TO KNOW MORE ABOUT OUR COMMITMENT TO R&D AND INNOVATION
click here
| Our Commitment to R&D and Innovation |
Bracco Imaging devotes considerable effort and substantial resources to research and development (R&D), in order to create and develop innovative products addressing unmet or poorly met medical needs. Another R&D goal is the conception and implementation of high-efficiency production processes with special attention to minimise their environmental impact. Bracco Imaging carries out its R&D activities in the Research Centers of Colleretto Giacosa (Ivrea, Italy), Plan-les-Ouates (Geneva, Switzerland) and Princeton (New Jersey, USA). Our Group currently owns approximately 1500 patents registered throughout the world. Our history of developing proprietary products includes: iopamidol, the first ready-to-use, non-ionic / low osmolal contrast agent for X-Ray, launched in 1981 and still the leading product in many markets under different brand names; Iomeron®, launched in 1994, the ready-to-use, non-ionic / low osmolal contrast agent for X-Ray, with the highest iodine concentration on the market; MultiHance®, the MRI contrast agent with high relaxivity and dual route of excretion, launched in 1998; SonoVue®, the ultrasound contrast agent with the broadest range of applications, launched in 2001 and Cardiogen the first and only agent approved for cardiac positron emitting tomography (PET). The Group is currently engaged in the development of new imaging agents and solutions, specifically designed to improve patient management through increased accuracy in diagnoses. To read more about our commitment to R&D and innovation, click here.
|
||